Business Context and Reporting Period
Company: Cartesian Therapeutics, Inc. (formerly Selecta Biosciences, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: A clinical-stage biotechnology company developing mRNA cell therapies for autoimmune diseases. The company completed a merger with Old Cartesian Therapeutics in November 2023 and executed a 1-for-30 reverse stock split in April 2024. Revenue is derived primarily from collaboration and license agreements, with no product sales to date.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2024 |
Six Months Ended June 30, 2024 |
Six Months Ended June 30, 2023 |
|---|---|---|---|
| Total Revenue | $33,445 | $39,285 | $11,187 |
| Net Income (Loss) | $13,836 | $(42,988) | $(33,050) |
| Operating Expenses | $19,688 | $38,876 | $48,206 |
| Research & Development | $12,661 | $22,399 | $36,406 |
| General & Administrative | $7,027 | $16,477 | $11,800 |
| Cash, Cash Equivalents & Restricted Cash | $88,896 (as of June 30, 2024) | ||
| Accumulated Deficit | $(657,635) (as of June 30, 2024) |
Material Changes vs. Prior Period
- Revenue Surge: Revenue for the six months ended June 30, 2024, increased 249% to $39.3 million compared to $11.2 million in the prior year period. This was driven primarily by a $30.0 million development milestone recognized from the Sobi License agreement and revenue recognized upon the termination of the Astellas Agreement.
- Net Loss Widening: Despite the revenue increase, the net loss for the six months ended June 30, 2024, widened to $43.0 million from $33.1 million in the prior year. This was due to significant non-cash charges related to the change in fair value of the Contingent Value Right (CVR) liability ($36.8 million expense), forward contract liabilities ($6.9 million expense), and warrant liabilities ($2.9 million expense).
- Expense Reduction: Research and Development expenses decreased 38% to $22.4 million, largely due to headcount reductions implemented in 2023 and decreased contract license payments.
- Debt Extinguishment: The company fully extinguished its 2020 Term Loan in September 2023; consequently, interest expense was $0 for the current period compared to $1.6 million in the prior year.
Guidance, Outlook, and Risks
- Liquidity and Capital Resources: As of June 30, 2024, the company held $88.9 million in cash. Management expects this, combined with net proceeds of approximately $124.4 million from a July 2024 Private Placement (subsequent event), to fund operations for at least the next 12 months.
- Subsequent Financing: On July 2, 2024, the company entered into a purchase agreement for a private placement resulting in gross proceeds of approximately $130.0 million, issuing common stock and Series B Non-Voting Convertible Preferred Stock.
- Contingent Value Rights (CVR): The company has a significant CVR liability ($395.4 million as of June 30, 2024). 100% of milestone payments and royalties from the Sobi License and legacy asset dispositions are contractually obligated to be distributed to CVR holders, net of deductions. The company has no obligation to fund this liability from other sources.
- Internal Control Material Weakness: Management identified a material weakness in internal controls related to the documentation of assumptions for valuing in-process intangible assets and the CVR obligation. Remediation plans are underway.
- Risks: The company remains in a pre-commercial stage with an accumulated deficit of $657.6 million. Future profitability is uncertain and dependent on successful clinical trials, regulatory approvals, and the ability to secure additional capital.
Investor Verification Checklist
- CVR Liability Impact: Verify the specific terms of the CVR Agreement to understand the extent to which future milestone payments (e.g., the $30M Sobi milestone) will be distributed to CVR holders versus retained by the company.
- July 2024 Financing Terms: Review the terms of the Series B Preferred Stock issued in July 2024, specifically regarding conversion rights, voting limitations, and potential dilution to existing common shareholders.
- Internal Control Remediation: Monitor the progress of remediation for the material weakness in internal controls regarding asset valuation and CVR accounting.
- Collaboration Agreements: Confirm the status of the Sobi License (SEL-212) and the impact of the terminated Astellas and Takeda agreements on future revenue streams.
- Cash Runway: Assess the company's burn rate against the combined cash balance of ~$213 million (including subsequent financing) to validate the 12-month liquidity projection.